Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study

Carregando...
Imagem de Miniatura
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2017
Editora
ELSEVIER IRELAND LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ATHEROSCLEROSIS, v.263, p.393-397, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and aims: Achilles tendon xanthomas (ATX) are a sign of long-term exposure to high blood cholesterol in familial hypercholesterolemia (FH) patients, which have been associated with cardiovascular disease. We evaluated the ATX association with the presence and extent of subclinical coronary atherosclerosis in heterozygous FH patients. Methods: 102 FH patients diagnosed by US-MEDPED criteria (67% with genetically proven FH), with median LDL-C 279 mg/dL (interquartile range: 240; 313), asymptomatic for cardiovascular disease, underwent computed tomography angiography and coronary artery calcium (CAC) quantification. Subclinical coronary atherosclerosis was quantified by CAC, segment-stenosis (SSS) and segment-involvement (SIS) scores. Adjusted Poisson regression was used to assess the association of ATX with subclinical atherosclerosis burden as continuous variables. Results: Patients with ATX (n = 21, 21%) had higher LDL-C and lipoprotein(a) [Lp(a)] concentrations as well as greater CAC scores, SIS and SSS (p < 0.05). After adjusting for age, sex, smoking, hypertension, previous statin use, HDL-C, LDL-C and Lp(a) concentrations, there was an independent positive association of ATX presence with CAC scores (beta = 1.017, p < 0.001), SSS (beta = 0.809, p < 0.001) and SIS (beta = 0.640, p < 0.001). Conclusions: ATX are independently associated with the extension of subclinical coronary atherosclerosis quantified by tomographic scores in FH patients.
Palavras-chave
Atherosclerosis, Familial hypercholesterolemia, Xanthomas, Calcium score, Computed tomography
Referências
  1. AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827
  2. Alonso R, 2014, J AM COLL CARDIOL, V63, P1983
  3. Artieda M, 2005, FEBS LETT, V579, P4503, DOI 10.1016/j.febslet.2005.06.087
  4. Cheruvu C, 2016, J CARDIOVASC COMPUT, V10, P22, DOI 10.1016/j.jcct.2015.12.005
  5. Civeira F., 2005, VASE BIOL, V25, P1960
  6. de Isla L. Perez, 2017, CIRCULATION
  7. FERRIERES J, 1995, CIRCULATION, V92, P290
  8. GINSBERG HN, 1990, ARTERIOSCLEROSIS, V10, P256
  9. Jannes CE, 2015, ATHEROSCLEROSIS, V238, P101, DOI 10.1016/j.atherosclerosis.2014.11.009
  10. Langsted A, 2016, LANCET DIABETES ENDO, V4, P577, DOI 10.1016/S2213-8587(16)30042-0
  11. Mangili LC, 2016, ATHEROSCLEROSIS, V254, P73, DOI 10.1016/j.atherosclerosis.2016.09.010
  12. Miname MH, 2010, ATHEROSCLEROSIS, V213, P486, DOI 10.1016/j.atherosclerosis.2010.10.001
  13. Neefjes LA, 2011, ATHEROSCLEROSIS, V219, P721, DOI 10.1016/j.atherosclerosis.2011.09.052
  14. Oosterveer DM, 2010, EUR HEART J, V31, P1007, DOI 10.1093/eurheartj/ehp538
  15. Oosterveer DM, 2009, ATHEROSCLEROSIS, V207, P311, DOI 10.1016/j.atherosclerosis.2009.04.009
  16. de Isla LP, 2016, ARTERIOSCL THROM VAS, V36, P2004, DOI 10.1161/ATVBAHA.116.307514
  17. Raal FJ, 2012, ATHEROSCLEROSIS, V223, P262, DOI 10.1016/j.atherosclerosis.2012.02.019
  18. Santos RD, 2016, LANCET DIABETES ENDO, V4, P850, DOI 10.1016/S2213-8587(16)30041-9
  19. Santos RD, 2015, LANCET, V385, P307, DOI 10.1016/S0140-6736(14)61702-5
  20. Santos RD, 2014, J AM COLL CARDIOL, V63, P1990, DOI 10.1016/j.jacc.2013.12.049
  21. Tada H, 2015, AM J CARDIOL, V115, P724, DOI 10.1016/j.amjcard.2014.12.034
  22. Tsouli SG, 2005, EUR J CLIN INVEST, V35, P236, DOI 10.1111/j.1365-2362.2005.01484.x
  23. Tsouli SG, 2006, J LIPID RES, V47, P2208, DOI 10.1194/jlr.M600109-JLR200
  24. Medel DV, 2013, AM J CARDIOL, V111, P955, DOI 10.1016/j.amjcard.2012.12.012
  25. Yeboah J, 2012, JAMA-J AM MED ASSOC, V308, P788, DOI 10.1001/jama.2012.9624